125561 Page

It is an enzyme replacement therapy used to treat Lysosomal Acid Lipase (LAL) deficiency , a rare genetic condition.

The application was submitted by Alexion Pharmaceuticals and received FDA approval in September 2015 . Academic & Technical Research 125561

The number also serves as a specific article identifier (often part of a DOI or page reference) in various scientific journals: It is an enzyme replacement therapy used to

A paper titled " Optimal nonparametric inference via deep neural network " is indexed under this number (Article 125561) in the Journal of Mathematical Analysis and Applications . Another technical reference exists for "Deep fuzzy C-means

Another technical reference exists for "Deep fuzzy C-means clustering in a federated heterogeneous scenario," which uses a similar DOI sequence (10.1109/JAS.2025. 125561 ). Public Records & Evidence

Under number 125561 , written evidence was submitted by Mrs. C. Roche to the UK Parliament regarding the impact of screen time and "digital drugs" on children’s brains and ADHD .